Creative Biolabs is accelerating CAR‑T innovation, driving breakthroughs in solid tumor targeting. SHIRLEY, NY, UNITED ...
Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...
Within this global landscape, the EXO 001 targeted exosome platform--developed jointly by CMUH and Ever Supreme Bio Technology--stands out for its use of high-biocompatibility, naturally derived ...
A new generation of engineered immune cell destroys cancer cells in mice 1 as effectively as conventional CAR-T-cell ...
H2H will evaluate the efficacy and safety of rondecabtagene autoleucel (ronde-cel) versus Investigator’s choice of approved ...
Ever since 6-year-old Emily Whitehead became the first pediatric patient to receive CAR-T cell therapy in 2012, when T cells ...
MedPage Today on MSN
Prior ibrutinib may improve CAR-T efficacy in rare lymphoma
Findings could be practice changing if proven prospectively, experts say ...
Ibrutinib was a breakthrough when it was first approved to treat R/R MCL in 2013, and a year later for patients with at least 1 prior treatment for chronic lymphocytic leukemia. However, its ...
RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...
In the rapidly moving field, questions remain regarding long-term safety, durability of remission, and the FDA’s approach to ...
Symptoms and organ damage abated in young children and teenagers whose conditions had resisted other treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results